HUPO Association

B/D HPP
Human Liver Proteome Project (HLPP)

GET INVOLVED: Get in touch at office@hupo.org to learn more
Mission & Goals
The liver is a central organ in human body that controls metabolic homeostasis, provide essential substances to the organism and allow detoxification of xenobiotics. In addition to its biological function, liver physiology is peculiar in different aspects, including its regeneration capacity. Despite the intense research performed during the last couple of decades, there are still many open questions in regard of the molecular mechanisms underlying liver function and, most importantly, liver disease. This constraint largely restricts the development of more efficient diagnostic and therapeutic strategies for the better management of the patients. In the postgenomic era, the Human Liver Initiative started in 2002 as a large-scale international collaborative initiative aiming to define a comprehensive and dynamic map of the human liver proteome.
HLPP Membership
For more information or participation opportunities please contact us.
Leadership Information

Chair:
Daniel Martins-de-Souza, Ph.D
University of Campinas, Sao Paulo, Brazil 

Chair:
Melanie Föcking, Ph.D
Royal College of Surgeons, Dublin, Ireland 

Executive Committee Members:

Katrin Marcus, Ph.D Ruhr University, Bochum, Germany
Oliver Schubert, MD, Ph.D University of Adelaide, Adelaide, Australia
Peter Nilsson, Ph.D KTH – Royal Institute of Technology, Stockholm, Sweden
Robert Mccullumsmit, MD, Ph.D University of Toledo, Toledo, USA

 

Current Lines of Work

  • Definition of liver proteome by characterization of all specific liver cell types and their interaction in health and disease.
  • Definition of priority protein lists relevant in liver physiology and participating in the molecular pathogenesis of liver disorders. Example: panel of 15 enzymes of One Carbon Metabolism.
  • To develop targeted standardized methods for the quantification of clinically relevant proteins. Example: SRM assay for a panel of 12 enzymes of One Carbon Metabolism.
  • In depth dynamic characterization of liver regeneration by a combination of proteomics and phosphoproteomics.
  • To identify novel proteins relevant in liver biology and pathology by means of proteogenomics.
  • Identify differentially expressed proteins in Hepatocellular carcinoma (HCC) patients who underwent liver transplantaion, using proteomics of vascular invation, well differentiated, moderate differentiated, and poor differentiated liver biopsies
  • Non Alcoholic Fatty Liver Disease (NAFLD) molecular characterization and early marker discovery.
  • Analysis of molecular mechanisms in drug induced liver injury.
  • To study the role of ubiquitin-like proteins in liver disease.

Publications:

Liver cancer-associated changes to the proteome: what deserves clinical focus?
Bioengineered PBGD variant improves the therapeutic index of gene therapy vectors for acute intermittent porphyria
Abundance of Cytochromes in Hepatic Extracellular Vesicles Is Altered by Drugs Related With Drug-Induced Liver Injury
SUMOylation regulates LKB1 localization and its oncogenic activity in liver cancer
Prohibitin 1 Acts As a Negative Regulator of Wingless/Integrated-Beta-Catenin Signaling in Murine Liver and Human Liver Cancer Cells
Obeticholic Acid Modulates Serum Metabolites and Gene Signatures Characteristic of Human NASH and Attenuates Inflammation and Fibrosis Progression in Ldlr-/-Leiden Mice
The mitochondrial chaperone Prohibitin 1 negatively regulates interleukin-8 in human liver cancers
MiR-873-5p acts as an epigenetic regulator in early stages of liver fibrosis and cirrhosis
Repurposing ciclopirox as a pharmacological chaperone in a model of congenital erythropoietic porphyria
Fine-tuning of SIRT1 expression is essential to protect the liver from cholestatic liver disease
Liver cancer-associated changes to the proteome: what deserves clinical focus?
Metabolomic-based noninvasive serum test to diagnose nonalcoholic steatohepatitis: Results from discovery and validation cohorts
Mechanisms of MAFG Dysregulation in Cholestatic Liver Injury and Development of Liver Cancer
Use of a metabolomic approach to non-invasively diagnose non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus
Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis C patients
Liver cancer cell lines distinctly mimic the metabolic gene expression pattern of the corresponding human tumours
A MAA-based dosimetric study in patients with intrahepatic cholangiocarcinoma treated with a combination of chemotherapy and 90Y-loaded glass microsphere selective internal radiation therapy
Direct Quantification of Cytochromes P450 and Drug Transporters-A Rapid, Targeted Mass Spectrometry-Based Immunoassay Panel for Tissues and Cell Culture Lysates
Mixture effects of two plant protection products in liver cell lines
Targeting Endothelial Erk1/2-Akt Axis as a Regeneration Strategy to Bypass Fibrosis during Chronic Liver Injury in Mice
ER-associated ubiquitin ligase HRD1 programs liver metabolism by targeting multiple metabolic enzymes
Artificial MicroRNA-Mediated Tgfbr2 and Pdgfrb Co-Silencing Ameliorates Carbon Tetrachloride-Induced Hepatic Fibrosis in Mice
Germline Duplication of SNORA18L5 Increases Risk for HBV-related Hepatocellular Carcinoma by Altering Localization of Ribosomal Proteins and Decreasing Levels
A proteomics landscape of circadian clock in mouse liver
Dysregulated Response of Follicular Helper T Cells to Hepatitis B Surface Antigen Promotes HBV Persistence in Mice and Associates With Outcomes of Patients

Other HUPO INITIATIVES:

Industrial Advisory Board (IAB) Members

Scroll to Top

Job Posting Enquiry

Fill out the form below, and we will be in touch shortly.
Name